A pan-tumor review of the role of poly(adenosine diphosphate ribose) polymerase inhibitors.

92 At 76.8% maturity, there was a trend toward improved OS with olaparib; however, it did not reach statistical significance (median OS, 19.3 vs. 17.1 months; HR, 0.89; 95% CI, 0.67–1.18). 100 In an exploratory analysis of patients who received olaparib as a first‐line treatment in the metastatic setting, the median OS was significantly longer compared with that in those who received the standard therapy (22.6 vs. 14.7 months; HR, 0.55; 95% CI, 0.33–0.95). 100 The most frequent AEs with olaparib were nausea (58%), anemia (40%), and vomiting (32.2%).

also in 111,027 other papers

Patients with non‐HRRm disease had a nonsignificant trend toward an improved OS with the combination of olaparib plus abiraterone (median OS, 42.1 vs. 38.9 months; HR, 0.89; 95% CI, 0.70–1.14).

also in 5,406 other papers